TIDMAKR
RNS Number : 5176G
Akers Biosciences, Inc.
23 November 2015
23 November 2015
Akers Biosciences, Inc.
Akers Biosciences Appoints Medical Technology Specialist as
CEO
Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), ("Akers
Bio" or the "Company"), a medical device company focused on
reducing the cost of healthcare through faster, easier diagnostics,
is pleased to announce the appointment of John J. Gormally as Chief
Executive Officer.
John joins Akers Bio following a highly successful career -
spanning over 30 years - with the global medical technology company
Becton Dickinson. His most recent position with Becton Dickinson
was as Vice President, US Region Business Leader of Preanalytical
Systems with responsibility for the sample collection, venous
access and the molecular diagnostic business platforms. John helped
successfully grow annual business revenues by more than $80 million
in a business unit that contributed annual revenues of over $650
million. He led a multi-functional team of 92 associates including
sales, marketing and finance teams.
Prior to this role, John was Vice President, Worldwide Sales of
Preanalytical Systems, leading a global sales function with 256
associates and annual revenues of $1.1 billion. During his five
years John contributed to revenue growth of $242 million in both
product volume and price - a period of record growth in revenue and
profitability for the business unit.
Before joining Preanalytical Systems, John held the position of
Vice President BD Diabetes Care with responsibility for the US sale
and distribution of diabetes care products and services and, in
particular, for launching a product for blood glucose monitoring.
John created and implemented a market strategy for the test,
including making the sales force accountable for superior results.
He successfully led a team of 57 associates with annual revenues of
$331 million. John exceeded revenue budgets with annual sales
growth of 8.4%.
John first joined Becton Dickinson in 1979 and climbed the sales
and management ranks over twenty years within the Medical Surgical,
Microbiology/Diagnostics and then Healthcare Systems divisions.
John left Becton Dickinson in 1999, for several years, to pursue an
opportunity with Bristol-Myers Squibb Company, a global
biopharmaceutical business which develops, licenses, manufactures,
markets and sells pharmaceutical and nutritional products. There he
was accountable for a sales force/operations team of 226, with $450
million in annual revenue.
He later joined BEI Medical Systems, a medical device start up,
as Vice President, Global Sales and Marketing. John developed a
highly successful commercial strategy and, from a zero base,
established a profitable business which was sold two years later,
in 2003, to Boston Scientific for $95 million (or 33 times
earnings). Following the sale, John was recruited back to Beckton
Dickinson.
John graduated with a B.S. Biology from DeSales University, PA
in 1978.
John J. Gormally is being appointed as an officer of the Company
but will not sit on the board of directors.
"John has highly relevant experience to lead the
commercialisation strategy at Akers Bio," said Raymond F. Akers,
Jr. PhD, Co-founder and Executive Chairman. "His expertise is in
commercial strategy design and execution. John has achieved
tremendous success both in leading Becton Dickinson business units
and in a smaller, early stage medical device business," continued
Dr. Akers.
"From an early stage in his career, John spent considerable time
selling directly to hospitals and hospital reference laboratories,
which are key customers for Akers Bio. He has tremendous experience
of developing sales strategies, leading direct sales teams and
managing relationships with distributors - including those with
whom Akers Bio already has relationships. These are all key
attributes for leading the commercial function at Akers Bio as we
seek to accelerate the domestic sales of our flagship test for
Heparin-Induced Thrombocytopenia and to launch new products into
the market, including within the valuable health and wellness
area," added Dr. Akers.
About Akers Biosciences, Inc.
Akers Biosciences develops, manufactures, and supplies rapid
screening and testing products designed to deliver quicker and more
cost-effective healthcare information to healthcare providers and
consumers. The Company has advanced the science of diagnostics
while responding to major shifts in healthcare through the
development of several proprietary platform technologies. The
Company's state-of-the-art rapid diagnostic assays can be performed
virtually anywhere in minutes when time is of the essence. The
Company has aligned with major healthcare companies and high volume
medical product distributors to maximize product offerings, and to
be a major worldwide competitor in diagnostics.
Additional information on the Company and its products can be
found at www.akersbio.com. Follow us on Twitter @AkersBio.
Cautionary Statement Regarding Forward Looking Statements
Statements contained herein that are not based upon current or
historical fact are forward-looking in nature and constitute
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange
Act of 1934. Such forward-looking statements reflect the Company's
expectations about its future operating results, performance and
opportunities that involve substantial risks and uncertainties.
These statements include but are not limited to statements
regarding the intended terms of the offering, closing of the
offering and use of any proceeds from the offering. When used
herein, the words "anticipate," "believe," "estimate," "upcoming,"
"plan," "target", "intend" and "expect" and similar expressions, as
they relate to Akers Biosciences, Inc., its subsidiaries, or its
management, are intended to identify such forward-looking
statements. These forward-looking statements are based on
information currently available to the Company and are subject to a
number of risks, uncertainties, and other factors that could cause
the Company's actual results, performance, prospects, and
opportunities to differ materially from those expressed in, or
implied by, these forward-looking statements.
For more information:
Akers Biosciences, Inc.
Raymond F. Akers, Jr. PhD
Executive Chairman of the Board
Tel. +1 856 848 8698
Taglich Brothers, Inc. (Investor Relations)
Chris Schreiber
Tel. +1 917 445 6207
Email: cs@taglichbrothers.com
finnCap (UK Nominated Adviser and Broker)
Adrian Hargrave / Scott Mathieson (Corporate Finance)
Steve Norcross (Broking)
Tel. +44 (0)20 7220 0500
Vigo Communications (Public Relations)
Ben Simons / Fiona Henson
Tel. +44 (0)20 7016 9570
Email: akers@vigocomms.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCQBLFLEFFFFBD
(END) Dow Jones Newswires
November 23, 2015 02:00 ET (07:00 GMT)
Akers Biosciences (LSE:AKR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Akers Biosciences (LSE:AKR)
Historical Stock Chart
From Apr 2023 to Apr 2024